[EN] PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS<br/>[FR] ANALOGUES DE PYRIDONEMORPHINANE ET ACTIVITÉ BIOLOGIQUE SUR DES RÉCEPTEURS DES OPIOÏDES
申请人:PURDUE PHARMA LP
公开号:WO2014091295A1
公开(公告)日:2014-06-19
The application is directed to compounds of Formula (I-A) and pharmaceutically acceptable salts and solvates thereof, wherein Formula (II), R1a, R2a, R3a, R4 and Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
Partial molar volumes and heat capacities of the N-acetyl amide derivatives of the amino acids asparagine, glutamine, tyrosine, and lysine monohydrochloride in aqueous solution at temperatures from T=288.15K to T=328.15K
作者:Jin L. Liu、Andrew W. Hakin、Gavin R. Hedwig
DOI:10.1016/j.jct.2006.03.015
日期:2006.12
Abstract The partial molar volumes, V 2 ∘ , and partial molarheat capacities, C p , 2 ∘ , at infinite dilution have been determined for the compounds N -acetylasparaginamide, N -acetylglutaminamide, N -acetyltyrosinamide, and N -acetyllysinamide monohydrochloride in aqueous solution at T = (288.15, 298.15, 313.15, and 328.15) K. These results, along with the literature data for the compound N -acetylglycinamide
摘要 在无限稀释条件下,测定了化合物 N-乙酰天冬酰胺、N-乙酰谷氨酰胺、N-乙酰酪氨酸酰胺和 N-乙酰赖氨酰胺单盐酸盐水溶液的偏摩尔体积 V 2 ∘ 和偏摩尔热容 C p , 2 ∘ 。 T = (288.15, 298.15, 313.15, 和 328.15) K 时的溶液。这些结果,连同化合物 N-乙酰甘氨酰胺的文献数据,已被用于计算氨基酸侧链对热力学性质的贡献。将这些侧链贡献与使用小肽作为侧链模型化合物获得的贡献进行比较。
[EN] PROPELLANE-BASED COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR MODULATORS<br/>[FR] COMPOSÉS À BASE DE PROPELLANE ET UTILISATION DE CES DERNIERS EN QUALITÉ DE MODULATEURS DE RÉCEPTEURS D'OPIOÏDES
申请人:PURDUE PHARMA LP
公开号:WO2015097546A1
公开(公告)日:2015-07-02
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R'-R3 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I) to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.